Ningbo Menovo Pharmaceutical's (SHSE:603538) Problems Go Beyond Weak Profit

A lackluster earnings announcement from Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

Check out our latest analysis for Ningbo Menovo Pharmaceutical

The Impact Of Unusual Items On Profit

To properly understand Ningbo Menovo Pharmaceutical's profit results, we need to consider the CN¥25m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Ningbo Menovo Pharmaceutical's positive unusual items were quite significant relative to its profit in the year to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Ningbo Menovo Pharmaceutical's Profit Performance

As we discussed above, we think the significant positive unusual item makes Ningbo Menovo Pharmaceutical's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Ningbo Menovo Pharmaceutical's underlying earnings power is lower than its statutory profit. In further bad news, its earnings per share decreased in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example - Ningbo Menovo Pharmaceutical has 3 warning signs we think you should be aware of.

This note has only looked at a single factor that sheds light on the nature of Ningbo Menovo Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.